ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022.
(C)2019 ENPublishing - http://www.enpublishing.co.uk
Release date- 26072019 - Geneva - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the Independent Data Monitoring Committee (IDMC) has completed the unblinded review of data from the first 30 subjects randomized in Part B of the PROLONG trial in preterm labor with PGF2a receptor antagonist OBE022.
An IDMC is an independent panel of experts who periodically review clinical trial data to ensure that the interests of the patients are being well-served and that the scientific integrity of the trial is maintained.
In the PROLONG trial, OBE022 or matching placebo is administered daily for 7 days to pregnant women who are receiving an infusion of atosiban for 48 hours, the current standard of care therapy for preterm labor in the countries in which the PROLONG trial is being conducted. The goal is to assess the efficacy, safety and pharmacokinetics of OBE022 in patients with threatened spontaneous preterm labor.
'We are very pleased to have initial feedback from the Part B of the PROLONG trial,' said Ernest Loumaye, co-founder and Chief Executive Officer of ObsEva. 'The IDMC reviewed the data from the first 30 subjects randomized in PROLONG and recommended to continue the trial without modifications. This is very positive feedback on OBE022, a potential first-in-class molecule being developed for the treatment of preterm labor, and we continue progressing towards the completion of the trial with the next IDMC review expected with data from 60 patients later this year. '
PROLONG is a proof-of-concept Phase 2a clinical trial conducted in two parts: Part A and Part B.
Part A was an open-label single arm trial of OBE022 administered orally for 7 days to pregnant women with nine subjects enrolled. OBE022 was well tolerated by the mothers and their fetuses and the pharmacokinetics of OBE022 were similar to those previously observed in non-pregnant women.
Part B, is a randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy, safety and pharmacokinetics of OBE022. The trial will recruit 120 patients with preterm labor at a gestational age of 24 to 34 weeks. OBE022 or placebo is administered orally, with 1000 mg as a starting dose, then 500 mg twice a day for 7 days to women already receiving a standard-of-care therapy for threatened preterm labor, an atosiban infusion for 48 hours. The regimen is the same as in Part A.
Part B is being conducted in Czech Republic, Finland, Israel, Russia, Spain and Vietnam.
About Preterm Labor
Preterm labor, defined as the birthing process starting prior to 37 weeks of gestation, is a serious condition characterized by uterine contractions, cervical dilation and rupture of the fetal membranes that can lead to preterm birth. According to a study published in the Lancet in 2012, approximately 15 million babies were born before 37 weeks of gestation in 2010, accounting for 11.1% of all live births worldwide. Over 1 million children under the age of five died in 2013 worldwide due to preterm birth complications, and many infants who survive preterm birth are at greater risk for cerebral palsy, delays in development, hearing and vision issues, and often face a lifetime of disability. The rates of preterm births are rising in almost all countries with reliable data for preterm birth, and are associated with an immense financial impact to the global healthcare system.
To date, only treatments with limited efficacy or restrictive safety issues are available to treat preterm labor. In the United States, no drugs are approved for acute treatment of PTL and recommended off-label tocolytic treatments (medications that inhibit labor) include beta-adrenergic receptor agonists, calcium channel blockers, or NSAIDs, which are used for short-term prolongation of pregnancy (up to 48 hours) to allow for the administration of antenatal steroids (e.g. betamethasone). Magnesium sulfate, used for fetal neuroprotection can also be used (up to 48 hours) to inhibit acute preterm labor. Approved tocolytic treatments in Europe include beta-adrenergic agonists, which carry severe maternal cardiovascular risks, and intravenous infusions of atosiban (an oxytocin receptor antagonist).
While prostaglandin inhibitors (NSAIDs) have been shown to be effective for inhibiting preterm labor, use of such drugs is limited, due to the threat of serious and sometimes life-threatening side effects in the fetus. Such side effects may include kidney function impairment, premature constriction of the blood vessel connecting the pulmonary artery and the descending aorta in a developing fetus (ductus arteriosus), and higher risk of thrombosis of the intestinal arteries (a condition called necrotizing enterocolitis).
About OBE022 and PGF2alpha
ObsEva is developing OBE022, a potential first-in-class, once daily, oral and selective prostaglandin F2alpha receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF2alpha is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that OBE022 markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with prostaglandin inhibitors such as indomethacin.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol 'OBSV' and on the SIX Swiss Exchange where it is trading under the ticker symbol 'OBSN'.
Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'believe', 'expect', 'may', 'plan,' 'potential,' 'will,' and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of OBE022 and the timing of enrollment in and data from clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later-stage clinical trials, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2018, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Tel: +41 22 308 6220
[Editorial queries for this story should be sent to email@example.com]
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 29, 2019|
|Previous Article:||NICE - Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund.|
|Next Article:||GPhC announces pass rates for June 2019 registration assessment.|